Profile data is unavailable for this security.
About the company
Trinity Biotech PLC is an Ireland-based develops, acquires, manufactures and markets medical diagnostic systems, including both reagents and instrumentation for the clinical laboratory and point-of-care segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes and disorders of the liver and intestine. Its segments include the Americas and Rest of World. It is a provider of raw materials to the life sciences and research industries globally. It also operates a licensed reference laboratory that specializes in diagnostics for autoimmune diseases. Its POC brands include Uni-Gold, Recombigen, MarDx, FlexTrans, Premier and Ultra. Its clinical laboratory brands include ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ. The Company manufactures kits for the detection of specialty and esoteric biomarkers of infectious diseases and other associated laboratory products.
- Revenue in USD (TTM)56.71m
- Net income in USD-33.88m
- Incorporated1992
- Employees380.00
- LocationTrinity Biotech PLCIda Business ParkBray, Co Wicklow, IrelandBRAY 18IrelandIRL
- Phone+353 12769800
- Fax+353 12769888
- Websitehttps://www.trinitybiotech.com/
More ▼
Mergers & acquisitions
| Acquired company | TRIB:NSQ since announced | Transaction value |
|---|---|---|
| Waveform Technologies Inc-Continuous Glucose Monitoring Assets | 5.07% | 21.50m |
Data delayed at least 15 minutes, as of Jun 10 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| KALA BIO Inc | 0.00 | -39.55m | 18.50m | 43.00 | -- | 2.78 | -- | -- | -15.15 | -15.15 | 0.00 | 2.37 | 0.00 | -- | -- | 0.00 | -63.15 | -57.83 | -76.71 | -69.32 | -- | 57.06 | -- | -1,553.61 | -- | -12.26 | 0.8382 | -- | -100.00 | -- | 5.85 | -- | -17.31 | -- |
| MEI Pharma Inc | 66.75m | 26.16m | 19.12m | 46.00 | 0.7311 | 0.3747 | 0.7213 | 0.2865 | 3.93 | 3.93 | 10.02 | 7.66 | 0.6498 | -- | 29.15 | 1,451,174.00 | 25.46 | -25.31 | 30.38 | -28.59 | -- | -- | 39.18 | -122.05 | -- | -- | 0.00 | -- | 19.95 | 97.56 | 41.53 | -- | -- | -- |
| Neurobo Pharmaceuticals Inc | 0.00 | -16.58m | 19.28m | 8.00 | -- | 1.91 | -- | -- | -3.26 | -3.26 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -68.36 | -95.57 | -108.01 | -135.64 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.72 | -- | 75.54 | -- |
| Lyra Therapeutics Inc | 1.68m | -68.88m | 19.53m | 109.00 | -- | 0.252 | -- | 11.63 | -1.23 | -1.23 | 0.0297 | 1.27 | 0.0143 | -- | -- | 19,090.91 | -58.52 | -58.01 | -68.02 | -68.69 | -- | -- | -4,099.82 | -6,235.31 | -- | -- | 0.00 | -- | 14.31 | 4.60 | -13.39 | -- | 95.14 | -- |
| Cumberland Pharmaceuticals, Inc. | 38.83m | -8.42m | 19.73m | 91.00 | -- | 0.716 | -- | 0.5081 | -0.596 | -0.596 | 2.72 | 1.94 | 0.4542 | 0.8812 | 3.08 | 426,654.70 | -9.83 | -7.03 | -14.07 | -9.52 | 83.54 | 79.95 | -21.65 | -17.64 | 1.21 | -37.10 | 0.3717 | -- | -5.85 | 6.15 | -12.73 | -- | -36.17 | -- |
| Neurosense Therapeutics Ltd | 0.00 | -11.28m | 19.84m | 16.00 | -- | -- | -- | -- | -0.7625 | -0.7625 | 0.00 | -0.1219 | 0.00 | -- | -- | 0.00 | -207.24 | -- | -395.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.59 | -- | -- | -- |
| Trinity Biotech plc (ADR) | 56.71m | -33.88m | 19.88m | 380.00 | -- | -- | -- | 0.3505 | -4.42 | -2.81 | 7.41 | -14.96 | 0.625 | 1.69 | 3.67 | 149,229.00 | -37.34 | -20.30 | -47.55 | -29.54 | 34.21 | 39.92 | -59.75 | -29.86 | 1.03 | -1.96 | 1.36 | -- | -9.10 | -10.15 | 15.41 | -- | -31.08 | -- |
| Allied Corp | 21.51k | -9.00m | 20.11m | -- | -- | -- | -- | 934.69 | -0.0915 | -0.0915 | 0.0002 | -0.0711 | 0.0051 | 1.65 | 0.1441 | -- | -214.39 | -- | -- | -- | -6,919.57 | -- | -41,861.41 | -- | 0.0333 | -31.86 | -- | -- | -56.46 | -- | 31.30 | -- | -- | -- |
| Lumos Pharma Inc | 1.53m | -37.13m | 20.13m | 33.00 | -- | 1.15 | -- | 13.20 | -4.59 | -4.59 | 0.1886 | 2.15 | 0.0332 | -- | 8.01 | 46,212.12 | -80.89 | -29.78 | -90.15 | -32.32 | -- | -- | -2,434.69 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Bullfrog AI Holdings, Inc. | 65.00k | -5.95m | 20.65m | 4.00 | -- | 3.03 | -- | 317.65 | -0.8903 | -0.8903 | 0.0097 | 0.8667 | 0.0094 | -- | -- | 16,250.00 | -85.49 | -- | -103.85 | -- | 92.00 | -- | -9,129.42 | -- | -- | -278.20 | 0.0694 | -- | 550.00 | -- | -91.11 | -- | -- | -- |
| Ibio Inc | 50.00k | -17.13m | 20.87m | 26.00 | -- | 0.829 | -- | 417.39 | -13.10 | -17.09 | 0.0262 | 2.92 | 0.0011 | -- | 0.0065 | 1,923.08 | -36.24 | -28.09 | -67.39 | -32.63 | -- | -- | -34,258.00 | -1,467.30 | -- | -- | 0.3666 | -- | -100.00 | -- | 0.9764 | -- | 42.90 | -- |
| Polypid Ltd | 0.00 | -24.25m | 20.92m | 59.00 | -- | 2.93 | -- | -- | -12.35 | -12.35 | 0.00 | 1.49 | 0.00 | -- | -- | 0.00 | -84.94 | -76.92 | -120.03 | -89.61 | -- | -- | -- | -- | -- | -28.72 | 0.5498 | -- | -- | -- | 39.67 | -- | -42.34 | -- |
| Vincerx Pharma Inc | 0.00 | -38.25m | 21.03m | 42.00 | -- | -- | -- | -- | -1.79 | -1.79 | 0.00 | -0.029 | 0.00 | -- | -- | 0.00 | -130.68 | -- | -205.70 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 36.24 | -- | -- | -- |
| Zivo Bioscience Inc | 63.37k | -7.08m | 21.15m | 8.00 | -- | -- | -- | 333.83 | -3.83 | -3.83 | 0.0318 | -0.8133 | 0.0652 | -- | -- | 7,921.25 | -728.52 | -376.60 | -- | -- | 38.05 | -- | -11,176.47 | -96,315.32 | -- | -88.46 | -- | -- | -- | -- | 11.07 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -32.14m | 21.25m | 11.00 | -- | 0.7398 | -- | -- | -1.03 | -1.03 | 0.00 | 0.7882 | 0.00 | -- | -- | 0.00 | -93.54 | -72.06 | -104.30 | -82.27 | -- | -- | -- | -491,850.00 | -- | -- | 0.00 | -- | -- | -- | -126.79 | -- | -46.29 | -- |
| Bioxytran Inc | 0.00 | -4.30m | 21.26m | 2.00 | -- | -- | -- | -- | -0.0297 | -0.0297 | 0.00 | -0.0017 | 0.00 | -- | -- | -- | -2,431.80 | -1,420.53 | -- | -- | -- | -- | -- | -- | -- | -7.69 | -- | -- | -- | -- | -73.71 | -- | -- | -- |
Data as of Jun 10 2024. Currency figures normalised to Trinity Biotech PLC's reporting currency: US Dollar USD
50.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Apr 2024 | 2.72m | 35.60% |
| Hunter Associates Investment Management LLCas of 31 Mar 2024 | 317.81k | 4.16% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 267.35k | 3.50% |
| Stonehill Capital Management LLCas of 31 Mar 2024 | 248.40k | 3.25% |
| Acadian Asset Management LLCas of 31 Mar 2024 | 116.28k | 1.52% |
| Whitefort Capital Management, LPas of 31 Mar 2024 | 81.90k | 1.07% |
| Moss Adams Wealth Advisors LLCas of 31 Mar 2024 | 25.67k | 0.34% |
| Cambridge Investment Research Advisors, Inc.as of 31 Mar 2024 | 22.28k | 0.29% |
| Becker Capital Management, Inc.as of 31 Mar 2024 | 18.00k | 0.24% |
| G1 Execution Services LLCas of 31 Mar 2024 | 13.57k | 0.18% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
